1. Mibefradil is a novel Ca2+ antagonist which blocks both high-voltage activated and low voltage activated Ca2+ channels. Although L-type Ca2+ channel block was demonstrated in functional experiments its molecular interaction with the channel has not yet been studied. We therefore investigated the binding of [3H]-mibefradil and a series of mibefradil analogues to L-type Ca2+ channels in different tissues. 2. [3H]-Mibefradil labelled a single class of high affinity sites on skeletal muscle L-type Ca2+ channels (K(D) of 2.5 ± 0.4 nM, B(max) = 56.4 ± 2.3 pmol mg-1 of protein). 3. Mibefradil (and a series of analogues) partially inhibited (+)-[3H]-isradipine binding to skeletal muscle membranes but stimulated binding to brain L-type Ca2+ channels and α1C-subunits expressed in tsA201 cells indicating a tissue-specific, non-competitive interaction between the dihydropyridine and mibefradil binding domain. 4. [3H]-Mibefradil also labelled 3 heterogenous population of high affinity sites in rabbit brain which was inhibited by a series of nonspecific Ca2+ and Na+-channel blockers. 5. Mibefradil and its analogue RO40-6040 had high affinity for neuronal voltage-gated Na+-channels as confirmed in binding (apparent K(i) values of 17 and 1.0 nM, respectively) and functional experiments (40% use-dependent inhibition of Na+-channel current by 1 μM mibefradil in GH3 cells). 6. Our data demonstrate that mibefradil binds to voltage-gated L-type Ca2+ channels with very high affinity and is also a potent blocker of voltage-gated neuronal Na+-channels. More lipophilic mibefradil analogues may possess neuroprotective properties like other nonselective Ca2+-/Na+-channel blockers.
All Science Journal Classification (ASJC) codes
- Sodium channel blockers